Research programme: therapeutic proteins - TheraPten

Drug Profile

Research programme: therapeutic proteins - TheraPten

Alternative Names: TPT-612; TPT-612/ES; TPT-612/GBM; TPT-612/MM; TPT-612/RCC; TPT-612/TNBC; TPT-612/X; TPT-613; TPT-613/TNBC

Latest Information Update: 17 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TheraPten Biosciences
  • Developer National Research Council Canada; TheraPten Biosciences
  • Class Antineoplastics; Tumour suppressor proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 13 Apr 2017 9214364 - New profile
  • 13 Apr 2017 TheraPten files for patent protection for therapeutic proteins
  • 03 Apr 2017 Preclinical trials in Solid tumours in Canada (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top